ArticleVirchows Archiv : an international journal of pathology2025

HER2/CEP17 ratio predicts residual cancer burden after neoadjuvant dual HER2 blockade: real-world data in patients with primary HER2-amplified breast cancer.

Myriam Stolz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.